BioCentury: New cost-effectiveness model aims to better capture value of medicines to society
No Patient Left Behind’s updated methodology accounts for disease severity, loss of market exclusivity and social value
Measuring the damage: IRA’s impact on small molecule drug development
Read what one oncology executive discovered when he surveyed the biotech community.
BioCentury: Biotech leaders call on peers to lobby for IRA change
Letter calls nine-year price-setting threshold a threat to entire industry
RealClearHealth: For Two Years, Australia Failed People With Cystic Fibrosis; It Can’t Happen Again
Governments around the world have withheld access to life-changing medications for people with cystic fibrosis (CF) for years in the name of being hawkish on drug pricing.
BioCentury: KOLs call for updated Build Back Better to level playing field
Biopharma CEOs, investors call for same timeline for biologics, small molecules and lower out-of-pocket costs
Timmerman Report: Aducanumab & the Alzheimer’s Moonshot: What Would It Be Worth to Keep Your Mind?
Alzheimer’s and diseases like it have horrible costs on individuals, caregivers, and their families. A treatment for Alzheimer’s would not only relieve suffering for the patient and their family, but it would increase the productivity of millions of Americans and lower direct and indirect costs associated with care. And, once the treatment becomes generic, it will permanently upgrade human health for much less.
